Clinico-pathological research for predictive factors of the treatment effects in radiation therapy combined with or without chemotherapy for lung cancer

周围型I期非小细胞肺癌立体定向体部放射治疗的5年总生存率、病因特异生存率和局部无进展生存率分别为63%、74%和72%。但肺鳞癌患者预后较差。EGFR突变的免疫组化研究表明，EGFR基因突变的异质性在各型肺癌中普遍存在。6B6抗体染色对EGFR突变具有特异性，被认为可用于筛选对EGFR TKI有效的患者。

In the patients with peripheral stage I non-small cell lung cancer treated with stereotactic body radiotherapy, the 5-year overall survival rate, cause-specific survival rate and local progression-free rate were 63%, 74% and 72%, respectively. But the patients with squamous cell carcinoma of the lung had a worse prognosis. The immunohistochemical study for EGFR mutation showed that the heterogeneity of gene mutation commonly developed in the various types of lung cancer. The 6B6 antibody staining was specific for EGFR mutation and considered to be useful for screening patients effective to EGFR TKI.